AnodyneWiki

Disable conformers
Collapse all
Light theme

Carisoprodol

Read
Carisoprodol
Carisoprodol
Molecular structure via molpic based on CDK
Rotamer
[]
Conformer structure via 3Dmol.js
Enable javascript to view conformer structure via 3Dmol.js
Physical properties
[]
260.33 g/mol [1]
AppearanceCrystals [1]
TasteSlightly bitter taste [1]
Melting point198 to 199 °F (NTP, 1992) [1]
Solubilityless than 1 mg/mL at 67.1 °F (NTP, 1992) [1]
1.9 [1]
Structural Identifiers
[]
C12H24N2O4 [1]
[2-(carbamoyloxymethyl)-2-methylpentyl] N-propan-2-ylcarbamate [1]
CCCC(C)(COC(=O)N)COC(=O)NC(C)C [1]
InChI=1S/C12H24N2O4/c1-5-6-12(4,7-17-10(13)15)8-18-11(16)14-9(2)3/h9H,5-8H2,1-4H3,(H2,13,15)(H,14,16) [1]
InChIKeyOFZCIYFFPZCNJE-UHFFFAOYSA-N [1]
Pharmacokinetics[]
Elimination half-life2.5 hours [12 hours{-{refn|group=nb|At least 25% of the carisoprodol in the body is transformed by the liver into meprobamate, its main active metabolite, which in turn has a half-life of 10 hours.}-}]
Dosing[]
Oral
[]
Light≤ 125 mg(4x - 80%)
Common125 mg
Strong125 mg
Heavy125 - 290 mg
Extreme290 mg +(1x - 20%)
Intrarectal
[]
Light≤ 125 mg(14x - 87.5%)
Common125 mg
Strong125 mg
Heavy125 - 156.5 mg
Extreme156.5 mg +(2x - 12.5%)
Statistically derived dosages via DBI-IGS
We do not take any responsibility for medical complications or loss of life sustained by following these dosages blindly.

Carisoprodol (also known as Carisoprodol, Isomeprobamate, Carisoprodate, SOMA, Carisoprodatum, Carisoma, Isobamate, Isoprothane, Sanoma or Flexartal)

Chemistry

 []

Carisoprodol is a racemic mixture of the .

(R)-CarisoprodolGenerated by the Chemistry Development Kit (http://github.com/cdk)
(S)-CarisoprodolGenerated by the Chemistry Development Kit (http://github.com/cdk)
Stereoisomer enumberation with rdkit

Pharmacology

In the () carisoprodol acts

Metabolism

Interactions []

CYP2C19induction / inhibition

Subjective effects []

bonzi / Carisoprodol []

Legal status []

  • Australia: Carisoprodol is a S4 substance.
  • Canada: Carisoprodol is a Schedule IV substance.[3][4]
  • United States: Carisoprodol is a Schedule I under the "Controlled Substances Act (CSA)".

See also []

  • Anodyne

    • External links []

    References []

    1. National Center for Biotechnology Information. PubChem Compound Summary for CID 2576, Carisoprodol. Accessed April 16, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/2576

    2. U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Carisoprodol. UNII: 21925K482H. Global Substance Registration System. Accessed April 16, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/21925K482H

    3. Soma Product information. March 14, 2003. Accessed April 16, 2026. https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=205

    4. Notice of consultation: Removing carisoprodol from the Prescription Drug List (PDL). February 18, 2025. Accessed April 16, 2026. https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/prescription-drug-list/notices-changes/consultation-removal-carisoprodol.html